SynBiotic SE (SBX.DE) Stock Analysis & Winston Score
SynBiotic SE is a German company that focuses on cannabis-based health and wellness products. It sells medicinal cannabis, CBD supplements, and related natural health products to pharmacies, medical patients, and wellness consumers. The company operates in the fast-growing but heavily regulated European cannabis market, primarily in Germany. SynBiotic makes money by selling its products directly and through pharmacy distribution channels. It is a small-cap company based in Germany, and its business has grown partly through acquiring smaller cannabis and natural health brands. However, the deeply negative operating margin shows the company is spending far more than it earns, which is a serious concern. The key growth driver is Germany's ongoing cannabis liberalization — Germany loosened its cannabis laws in 2024, which could expand the legal market — but the main risk is that SynBiotic must reach profitability before it runs out of financial runway.
Winston Score: 34/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (13/30)
- Growth: Weak (3/20)
- Cash Flow: Weak (1/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: €1.10
Market Cap: €5M
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: Deutsche Börse


